Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK Analysis

20250 citationsJournal Articlegold Open Access

Authors

ClinicalTrials.gov identifier, NCT03624127, NCT03611751.

Published in: Dermatology and Therapy

Volume 16, Issue 1, pp. 637-646

Field-Weighted Citation Impact: 0.00